Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cancers arise from multiple acquired mutations, which presumably occur over many years. Early stages in cancer development might be present years before cancers become clinically apparent. METHODS: We analyzed data from whole-exome sequencing of DNA in peripheral-blood cells from 12,380 persons, unselected for cancer or hematologic phenotypes. We identified somatic mutations on the basis of unusual allelic fractions. We used data from Swedish national patient registers to follow health outcomes for 2 to 7 years after DNA sampling. RESULTS: Clonal hematopoiesis with somatic mutations was observed in 10% of persons older than 65 years of age but in only 1% of those younger than 50 years of age. Detectable clonal expansions most frequently involved somatic mutations in three genes (DNMT3A, ASXL1, and TET2) that have previously been implicated in hematologic cancers. Clonal hematopoiesis was a strong risk factor for subsequent hematologic cancer (hazard ratio, 12.9; 95% confidence interval, 5.8 to 28.7). Approximately 42% of hematologic cancers in this cohort arose in persons who had clonality at the time of DNA sampling, more than 6 months before a first diagnosis of cancer. Analysis of bone marrow-biopsy specimens obtained from two patients at the time of diagnosis of acute myeloid leukemia revealed that their cancers arose from the earlier clones. CONCLUSIONS: Clonal hematopoiesis with somatic mutations is readily detected by means of DNA sequencing, is increasingly common as people age, and is associated with increased risks of hematologic cancer and death. A subset of the genes that are mutated in patients with myeloid cancers is frequently mutated in apparently healthy persons; these mutations may represent characteristic early events in the development of hematologic cancers. (Funded by the National Human Genome Research Institute and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“CHIP carriers have an about 13-fold increased risk of developing myeloid hematological malignancies and an increased risk of all-cause mortality, largely due to cardiovascular disease and stroke.1, 2, 3, 4”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [1]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clonal expansion of blood cells, called clonal hematopoiesis (CH), increases in prevalence with age and is associated with increased risk of hematologic malignancies, but also unexpectedly with increased risk of cardiovascular disease20,21, likely through inflammatory effects of mutant cells22.”
From Somatic cancer variants enriched in Alzheimer’s disease microglia-like cells drive inflammatory and proliferative states (2026) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This state of abnormal HSC expansion without overt hematologic disease is known as clonal hematopoiesis (CH), and is associated with increased risk of cardiovascular events and blood cancers (3)(4)(5).”
From Txnip Enhances Fitness of Dnmt3a -Mutant Hematopoietic Stem Cells via p21 (2022) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CHIP carriers have an about 13-fold increased risk of developing myeloid hematological malignancies and an increased risk of all-cause mortality, largely due to cardiovascular disease and stroke.1, 2, 3, 4”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Loss-of-function heterozygous mutations in epigenetic regulators DNMT3A (cytosine methyltransferase) and TET2 (methylcytosine dioxygenase) are the most frequently detected mutations in CHIP, accounting for about 50% to 60% and 10% to 30% of mutations found in CHIP carriers, respectively.1, 2, 3,7,8”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [1]
Experimental — accuracy not yet measured
21 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738
Nowell, P. C. (1976) · Science · doi:10.1126/science.959840 · Cited by 6,471
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
Kralovics, R., Passamonti, F., Buser, A. S., Teo, S.-S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., & Skoda, R. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051113 · Cited by 3,470 · cited 15×
“Busque L, Patel JP, Figueroa ME, et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis.”
BackgroundInfluentialDiscovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Self-citationCOSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Ding, L., Ley, T. J., Larson, D. E., Miller, C. A., Koboldt, D. C., Welch, J. S., Ritchey, J. K., Young, M. A., Lamprecht, T., McLellan, M. D., et al. (2012) · Nature · doi:10.1038/nature10738 · Cited by 1,993
DNMT3A Mutations in Acute Myeloid Leukemia
Ley, T. J., Ding, L., Walter, M. J., McLellan, M. D., Lamprecht, T., Larson, D. E., Kandoth, C., Payton, J. E., Baty, J., Welch, J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005143 · Cited by 1,983
Mutation in TET2 in Myeloid Cancers
Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810069 · Cited by 1,776
Genome-wide association analysis identifies 13 new risk loci for schizophrenia
Multicenter Genetic Studies of Schizophrenia Consortium, Ripke, S., Psychosis Endophenotypes International Consortium, Wellcome Trust Case Control Consortium 2, O'Dushlaine, C., Chambert, K., Moran, J. L., Kähler, A. K., Akterin, S., Bergen, S. E., et al. (2013) · Nature Genetics · doi:10.1038/ng.2742 · Cited by 1,496
Self-citation
Cited by
Items 301–400 of 1,031
Myeloproliferative neoplasms: from origins to outcomes
Nangalia, J., & Green, A. R. (2017) · Blood · doi:10.1182/blood-2017-06-782037 · Cited by 158
“Third, no known oncogenic drivers can be identified from analysis of whole-exome or wholegenome sequencing in up to half of individuals with CH, suggesting that oncogene-independent mechanisms, such as clonal drift or reduced bone marrow genetic diversity, can lead to clonal expansion.(86,88) It is recognized that HSC…”
BackgroundSomatic Mutations in “Benign” Disease
Mustjoki, S., & Young, N. S. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2101920 · Cited by 166
Diagnosis and treatment of macrocytic anemias in adults
Nagao, T., & Hirokawa, M. (2017) · Journal of General and Family Medicine · doi:10.1002/jgf2.31 · Cited by 165
TET2-mutant clonal hematopoiesis and risk of gout
Agrawal, M., Niroula, A., Cunin, P., McConkey, M., Shkolnik, V., Kim, P. G., Wong, W. J., Weeks, L. D., Lin, A. E., Miller, P. G., et al. (2022) · Blood · doi:10.1182/blood.2022015384 · Cited by 160
Dnmt3a -mutated clonal hematopoiesis promotes osteoporosis
Kim, P. G., Niroula, A., Shkolnik, V., McConkey, M., Lin, A. E., Słabicki, M., Kemp, J. P., Bick, A., Gibson, C. J., Griffin, G., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20211872 · Cited by 164
Fuster, J. J., & Walsh, K. (2018) · Circulation Research · doi:10.1161/circresaha.117.312115 · Cited by 162
“Clonal hematopoiesis is often driven by a single mutation in a cancer-related gene, and, accordingly, it is associated with increased risk of hematologic malignancies.(35,36) Despite this, epidemiological studies show that most individuals carrying cancer-related somatic mutations that drive clonal expansion of the mu…”
BackgroundUnraveling Hematopoiesis through the Lens of Genomics
Liggett, L. A., & Sankaran, V. G. (2020) · Cell · doi:10.1016/j.cell.2020.08.030 · Cited by 163
“While the likelihood of CHIP increases with age, it appears in only a fraction of the population, and it increases the risk of cancer, cardiovascular disease, and other age-related morbidities (Bick et al., 2019a; Genovese et al., 2014; Jacobs et al., 2012; Jaiswal et al., 2014, 2017; Laurie et al., 2012; Xie et al.,…”
Tumor-Educated Platelets as Liquid Biopsy in Cancer Patients
Joosse, S. A., & Pantel, K. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.007 · Cited by 161
“Moreover,many aging people have benign tumors (e.g., skin tumors) or leukocytes carrying cancer-associatedmutations (Genovese et al., 2014), and this may cause false-positive findings.”
BackgroundLu, R., Wang, P., Parton, T., Zhou, Y., Chrysovergis, K., Rockowitz, S., Chen, W.-Y., Abdel-Wahab, O., Wade, P. A., Zheng, D., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.05.008 · Cited by 156
Cell competition in development, homeostasis and cancer
van Neerven, S. M., & Vermeulen, L. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-022-00538-y · Cited by 177
Luo, H., Mu, W.-C., Karki, R., Chiang, H.-H., Mohrin, M., Shin, J. J., Ohkubo, R., Ito, K., Kanneganti, T.-D., & Chen, D. (2019) · Cell Reports · doi:10.1016/j.celrep.2018.12.101 · Cited by 161
“…have shown that aging is associated with the accumulation of somatic mutations in the hematopoietic system and expansion of the mutated blood cells, a phenomenon termed clonal hematopoiesis (Busque et al., 2012; Genovese et al., 2014; Jaiswal et al., 2014; McKerrell et al., 2015; Xie et al., 2014).”
Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling
Caiado, F., Kovtonyuk, L. V., Gonullu, N. G., Fullin, J., Boettcher, S., & Manz, M. G. (2023) · Blood · doi:10.1182/blood.2022016835 · Cited by 161
Clonal haematopoiesis and dysregulation of the immune system
Belizaire, R., Wong, W. J., Robinette, M. L., & Ebert, B. L. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00843-3 · Cited by 161
“In addition to an increased risk of developing a myeloid malignancy, individuals with mutations in haematological malignancy-associated genes consistently show higher all-cause mortality compared with individuals without mutations 75,76,78–84 .”
Circulating cell-free DNA for cancer early detection
Gao, Q., Zeng, Q., Wang, Z., Li, C., Xu, Y., Cui, P., Xin, Z., Lu, H., Wang, G., Cai, S., et al. (2022) · The Innovation · doi:10.1016/j.xinn.2022.100259 · Cited by 200
Krimmel, J. D., Schmitt, M. W., Harrell, M. I., Agnew, K. J., Kennedy, S. R., Emond, M. J., Loeb, L. A., Swisher, E. M., & Risques, R. A. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1601311113 · Cited by 158
Quek, L., Otto, G. W., Garnett, C., Lhermitte, L., Karamitros, D., Stoilova, B., Lau, I.-J., Doondeea, J., Usukhbayar, B., Kennedy, A., et al. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20151775 · Cited by 153
Levis, M. J., Perl, A. E., Altman, J. K., Gocke, C. D., Bahceci, E., Hill, J. E., Liu, C., Xie, Z., Carson, A. R., McClain, V., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018015925 · Cited by 167
“Alternatively, so-called “founder mutations,” such as DNMT3a or TET2, are less useful as markers of MRD, because they often define clonal hematopoiesis but not necessarily malignant hematopoiesis.(33,34) Furthermore, lesions in DNMT3a and TET2 are often missense mutations that may also be present as background noise i…”
BackgroundClonal evolution in myelodysplastic syndromes
da Silva-Coelho, P., Kroeze, L. I., Yoshida, K., Koorenhof-Scheele, T. N., Knops, R., van de Locht, L. T., de Graaf, A. O., Massop, M., Sandmann, S., Dugas, M., et al. (2017) · Nature Communications · doi:10.1038/ncomms15099 · Cited by 149
“Upon therapeutic reduction of the MDS clone a pattern resembling clonal haematopoiesis of indetermined potential may be observed, with clonal expansion of cells that do not carry any known driver mutation (like in UPN08) 28–30 .”
BackgroundHigh prevalence of myeloid neoplasms in adults with non–Langerhans cell histiocytosis
Papo, M., Diamond, E. L., Aubart, F. C., Emile, J., Roos‐Weil, D., Gupta, N., Durham, B. H., Özkaya, N., Doǧan, A., Ulaner, G. A., et al. (2017) · Blood · doi:10.1182/blood-2017-01-761718 · Cited by 165
“with an increased frequency of myeloid neoplasms due to acquisition of somatic mutations in genes commonly mutated in myeloid neoplasms.(30-32) Moreover, the lower survival rate”
TP53-mediated clonal hematopoiesis confers increased risk for incident atherosclerotic disease
Zekavat, S. M., Viana-Huete, V., Matesanz, N., Jorshery, S. D., Zuriaga, M. A., Uddin, M. M., Trinder, M., Paruchuri, K., Zorita, V., Ferrer-Pérez, A., et al. (2023) · Nature Cardiovascular Research · doi:10.1038/s44161-022-00206-6 · Cited by 146
Nagase, R., Inoue, D., Pastore, A., Fujino, T., Hou, H.-A., Yamasaki, N., Goyama, S., Saika, M., Kanai, A., Sera, Y., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20171151 · Cited by 155
“…reduced by RUNX1 mutant expression in KI mice, which presumably contributed to the transformation, although cell cycle arrest was found in LSK and progenitors of the mice with both mutations, as previously described in Runx1 mutant– expressing cord blood cells (Goyama et al., 2013; Fig.”
Genomic subtyping and therapeutic targeting of acute erythroleukemia
Iacobucci, I., Wen, J., Meggendorfer, M., Choi, J. K., Shi, L., Pounds, S. B., Carmichael, C. L., Masih, K. E., Morris, S. M., Lindsley, R. C., et al. (2019) · Nature Genetics · doi:10.1038/s41588-019-0375-1 · Cited by 155
Rowczenio, D. M., Gomes, S. M., Aróstegui, J. I., Mensa‐Vilaró, A., Omoyinmi, E., Trojer, H., Baginska, A., Baroja‐Mazo, A., Pelegrín, P., Savic, S., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01410 · Cited by 158
“Clonal non-malignant expansion of hematopoietic stem cells has recently been described in large scale sequencing studies in healthy adult subjects, in whom the frequency of clonal hematopoiesis increased from 1% in those over age 40 to about 10% by age 65 years (30, 32).”
Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms
Jayavelu, A. K., Schnoeder, T. M., Perner, F., Herzog, C., Meiler, A., Krishnamoorthy, G., Huber, N., Mohr, J., Edelmann-Stephan, B., Austin, R. J., et al. (2020) · Nature · doi:10.1038/s41586-020-2968-3 · Cited by 163
Comorbid and inflammatory characteristics of genetic subtypes of clonal hematopoiesis
Cook, E. K., Izukawa, T., Young, S., Rosen, G., Jamali, M., Zhang, L., Johnson, D., Bain, E., Hilland, J., Ferrone, C. K., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018024729 · Cited by 145
“This analytical cross-sectional study was designed before the known associations between CHIP and aging and selected clinical outcomes.(3,4) Our study aims were to 1.”
MethodKotini, A. G., Chang, C.-J., Chow, A., Yuan, H., Ho, T., Wang, T., Vora, S., Solovyov, A., Husser, C., Olszewska, M., et al. (2017) · Cell stem cell · doi:10.1016/j.stem.2017.01.009 · Cited by 163
Normanno, N., Cervantes, A., Ciardiello, F., De Luca, A., & Pinto, C. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.07.007 · Cited by 148
Neutrophils in aging and aging‐related pathologies
Avondt, K. V., Strecker, J., Tulotta, C., Minnerup, J., Schulz, C., & Soehnlein, O. (2022) · Immunological Reviews · doi:10.1111/imr.13153 · Cited by 165
Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia
Guièze, R., & Wu, C. J. (2015) · Blood · doi:10.1182/blood-2015-02-585042 · Cited by 148
“Moreover, recent studies have demonstrated that many cancer-driving genetic events were detectable in large population-based cohorts without hematological malignancies—so-called ‘clonal hematopoiesis’.(52,53) The frequency of these events increased with age and while the most mutations occurred in DNMT3A, TET2, ASXL1…”
BackgroundHrebien, S., Citi, V., Garcia-Murillas, I., Cutts, R., Fenwick, K., Kozarewa, I., McEwen, R., Ratnayake, J., Maudsley, R., Carr, T. H., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz085 · Cited by 146
“Age was not a significant factor in our cohort, likely reflecting the dominant effect of prior chemotherapy in this cohort, in contrast with the effect of age in healthy volunteers reports [23, 24].”
Chromosomal alterations among age-related haematopoietic clones in Japan
Terao, C., Suzuki, A., Momozawa, Y., Akiyama, M., Ishigaki, K., Yamamoto, K., Matsuda, K., Murakami, Y., McCarroll, S. A., Kubo, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2426-2 · Cited by 154
Self-citationPremature Menopause, Clonal Hematopoiesis, and Coronary Artery Disease in Postmenopausal Women
Honigberg, M. C., Zekavat, S. M., Niroula, A., Griffin, G. K., Bick, A. G., Pirruccello, J. P., Nakao, T., Whitsel, E. A., Farland, L. V., Laurie, C., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.051775 · Cited by 147
Self-citationLaying the foundation for genomically-based risk assessment in chronic myeloid leukemia
on behalf of the International CML Foundation Genomics Alliance, Branford, S., Kim, D. D. H., Apperley, J. F., Eide, C. A., Mustjoki, S., Ong, S. T., Nteliopoulos, G., Ernst, T., Chuah, C., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0512-y · Cited by 149
The Conundrum of Genetic “Drivers” in Benign Conditions
Kato, S., Lippman, S. M., Flaherty, K. T., & Kurzrock, R. (2016) · Journal of the National Cancer Institute · doi:10.1093/jnci/djw036 · Cited by 146
“blood cells from apparently healthy adults and were associated with future blood cancer risk (184).”
BackgroundOncogenic Roles and Inhibitors of DNMT1, DNMT3A, and DNMT3B in Acute Myeloid Leukaemia
Wong, K. K., Lawrie, C. H., & Green, T. (2019) · Biomarker Insights · doi:10.1177/1177271919846454 · Cited by 153
Aging-associated inflammation promotes selection for adaptive oncogenic events in B cell progenitors
Henry, C. J., Casás-Selves, M., Kim, J., Zaberezhnyy, V., Aghili, L., Daniel, A. E., Jimenez, L., Azam, T., McNamee, E. N., Clambey, E. T., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci83024 · Cited by 148
Germline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies
Saliba, J., Saint‐Martin, C., Stefano, A. D., Lenglet, G., Marty, C., Keren, B., Pasquier, F., Della-Valle, V., Secardin, L., Leroy, G., et al. (2015) · Nature Genetics · doi:10.1038/ng.3380 · Cited by 150
Mochizuki-Kashio, M., Aoyama, K., Sashida, G., Oshima, M., Tomioka, T., Muto, T., Wang, C., & Iwama, A. (2015) · Blood · doi:10.1182/blood-2015-03-634428 · Cited by 137
Buscarlet, M., Provost, S., Zada, Y. F., Bourgoin, V., Mollica, L., Dubé, M.-P., & Busque, L. (2018) · Blood · doi:10.1182/blood-2018-01-829937 · Cited by 146
Promises and Pitfalls of Using Liquid Biopsy for Precision Medicine
Rossi, G., & Ignatiadis, M. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3402 · Cited by 153
Multi-Modality Imaging in the Assessment of Cardiovascular Toxicity in the Cancer Patient
Plana, J. C., Thavendiranathan, P., Bucciarelli‐Ducci, C., & Lancellotti, P. (2018) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2018.06.003 · Cited by 161
“CH appears to be identified in approximately 10% of patients 70 to 79 years of age (18), with a 4-fold increased incidence in patients receiving cancer therapy when compared with untreated patients (19).”
BackgroundMolecular tumour boards — current and future considerations for precision oncology
Tsimberidou, A. M., Kahle, M., Vo, H. H., Baysal, M. A., Johnson, A., & Meric-Bernstam, F. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00824-4 · Cited by 144
Genetic hierarchy and temporal variegation in the clonal history of acute myeloid leukaemia
Hirsch, P., Zhang, Y., Tang, R., Joulin, V., Boutroux, H., Pronier, E., Moatti, H., Flandrin‐Gresta, P., Marzac, C., Bories, D., et al. (2016) · Nature Communications · doi:10.1038/ncomms12475 · Cited by 151
“In one third of our patients, neither recurrent CBF or MLL translocations, nor typical CHIP hierarchy or mutations in NPM1 , RUNX1 , CEBPA and GATA2 were found.”
InfluentialChristen, F., Hoyer, K., Yoshida, K., Hou, H., Waldhüter, N., Heuser, M., Hills, R. K., Chan, W., Hablesreiter, R., Blau, O., et al. (2019) · Blood · doi:10.1182/blood-2018-05-852822 · Cited by 153
Rolfo, C. D., Cardona, A. F., Cristofanilli, M., Paz-Ares, L. G., Díaz‐Mochon, J. J., Durán, I., Raez, L. E., Russo, A., Lorente, J. A., Malapelle, U., et al. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102978 · Cited by 154
Velten, L., Story, B. A., Hernández-Malmierca, P., Raffel, S., Leonce, D. R., Milbank, J., Paulsen, M., Demir, A., Szu-Tu, C., Frömel, R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21650-1 · Cited by 134
Combined landscape of single-nucleotide variants and copy number alterations in clonal hematopoiesis
Saiki, R., Momozawa, Y., Nannya, Y., Nakagawa, M. M., Ochi, Y., Yoshizato, T., Terao, C., Kuroda, Y., Shiraishi, Y., Chiba, K., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01411-9 · Cited by 149
Ness, K. K., Kirkland, J. L., Gramatges, M. M., Wang, Z., Kundu, M., McCastlain, K., Li-Harms, X., Zhang, J., Tchkonia, T., Pluijm, S. M. F., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.7467 · Cited by 140
“the most frequently and are associated with all-cause mortality and risk of hematologic cancer.(117,118) Recent data indicate that clonal hematopoiesis driver genes may not be responsible for this process in survivors of childhood cancer.”
BackgroundThe role of ASXL1 in hematopoiesis and myeloid malignancies
Asada, S., Fujino, T., Goyama, S., & Kitamura, T. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03084-7 · Cited by 152
Clonal hematopoiesis is associated with risk of severe Covid-19
Bolton, K. L., Koh, Y., Foote, M. B., Im, H., Jee, J., Sun, C. H., Safonov, A., Ptashkin, R., Moon, J. H., Lee, J. Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26138-6 · Cited by 143
Cancer Diagnosis Using a Liquid Biopsy: Challenges and Expectations
Castro-Giner, F., Gkountela, S., Donato, C., Alborelli, I., Quagliata, L., Ng, C. K. Y., Piscuoglio, S., & Aceto, N. (2018) · Diagnostics · doi:10.3390/diagnostics8020031 · Cited by 153
“Clearly, there is also a question of whether the residual false positive cases may be a result of the presence of age-related clonal hematopoiesis in asymptomatic patients [126], particularly in those genes that were previously implicated in hematological cancers [129,130].”
BackgroundDNA methylation as a transcriptional regulator of the immune system
Morales‐Nebreda, L., McLafferty, F. S., & Singer, B. D. (2018) · Translational research · doi:10.1016/j.trsl.2018.08.001 · Cited by 163
“Interestingly, the most common mutations found in clonal hematopoiesis of indeterminate potential are in the DNMT3A locus.(36,40,41) DNMT3A mutations have also been observed in patients with MDS and myeloproliferative neoplasms(42,43) and have been linked to secondary AML, suggesting these mutations might represent an…”
Valent, P., Orazi, A., Savona, M. R., Patnaik, M. M., Onida, F., van de Loosdrecht, A. A., Haase, D. T., Haferlach, T., Elena, C., Pleyer, L., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.222059 · Cited by 149
“In the earliest phases of clonal development, patients present without overt signs or symptoms of a hematopoietic neoplasm but their leukocytes carry one or more somatic mutations, usually (early, passenger-type) mutations otherwise also found in overt myeloid neoplasms (for example TET2 mutations).(67-70) In the cont…”
BackgroundMayrhofer, M., De Laere, B., Whitington, T., Van Oyen, P., Ghysel, C., Ampe, J., Ost, P., Demey, W., Hoekx, L., Schrijvers, D., et al. (2018) · Genome Medicine · doi:10.1186/s13073-018-0595-5 · Cited by 139
Self-citationIncidence and Burden of the Myelodysplastic Syndromes
Cogle, C. R. (2015) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-015-0269-y · Cited by 162
“278 Curr Hematol Malig Rep (2015) 10:272–281”
Nam, A. S., Dusaj, N., Izzo, F., Murali, R., Myers, R. M., Mouhieddine, T. H., Sotelo, J., Benbarche, S., Waarts, M., Gaiti, F., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01179-9 · Cited by 140
Nangalia, J., Nice, F. L., Wedge, D. C., Godfrey, A. L., Grinfeld, J., Thakker, C., Massie, C. E., Baxter, J., Sewell, D., Silber, Y., et al. (2015) · Haematologica · doi:10.3324/haematol.2015.129510 · Cited by 133
“These results accord with observations of clonal hematopoiesis in patients with essential thrombocythemia despite low allele burdens of JAK2,(9) and with reports of DNMT3A-associated clonal hematopoiesis in normal individuals.(10,11) In three patients, DNMT3A and JAK2 colonies were mutually exclusive (‘biclonal’ patie…”
ResultAge-related mutations and chronic myelomonocytic leukemia
Mason, C. C., Khorashad, J. S., Tantravahi, S. K., Kelley, T. W., Zabriskie, M. S., Yan, D., Pomicter, A. D., Reynolds, K. R., Eiring, A. M., Kronenberg, Z. N., et al. (2015) · Leukemia · doi:10.1038/leu.2015.337 · Cited by 140
Zhang, C. R. C., Nix, D., Gregory, M., Ciorba, M. A., Ostrander, E. L., Newberry, R. D., Spencer, D. H., & Challen, G. A. (2019) · Experimental Hematology · doi:10.1016/j.exphem.2019.11.008 · Cited by 137
“Despite the overall prevalence of CHIP, few of these individuals progress to hematopoietic malignancy [1, 2, 5, 7, 8].”
BackgroundUnnikrishnan, A., Papaemmanuil, E., Beck, D., Deshpande, N., Verma, A., Kumari, A., Woll, P. S., Richards, L. A., Knezevic, K., Chandrakanthan, V., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.06.067 · Cited by 146
“, 2012), albeit with an increased risk of acquiring hematological malignancy (Genovese et al., 2014; Jaiswal et al., 2014; Xie et al., 2014), it is possible that some of the clonal hematopoiesis observed upon AZA response may not have accompanying dysplasia.”
BackgroundGirelli, D., Marchi, G., & Camaschella, C. (2018) · HemaSphere · doi:10.1097/hs9.0000000000000040 · Cited by 165
Granulopoiesis and Neutrophil Homeostasis: A Metabolic, Daily Balancing Act
Yvan-Charvet, L., & Ng, L. G. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.05.004 · Cited by 129
Targeting Cardiac Stem Cell Senescence to Treat Cardiac Aging and Disease
Cianflone, E., Torella, M., Biamonte, F., De Angelis, A., Urbanek, K., Costanzo, F. S., Rota, M., Ellison-Hughes, G. M., & Torella, D. (2020) · Cells · doi:10.3390/cells9061558 · Cited by 132
Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy
Miller, P. G., Sperling, A. S., Brea, E. J., Leick, M. B., Fell, G. G., Jan, M., Gohil, S. H., Tai, Y.-T., Munshi, N. C., Wu, C. J., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004554 · Cited by 131
Bacher, U., Shumilov, E., Flach, J., Porret, N. A., Joncourt, R., Wiedemann, G., Fiedler, M., Novak, U., Amstutz, U., & Pabst, T. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0148-6 · Cited by 144
Mossner, M., Jann, J.-C., Wittig, J., Nolte, F., Fey, S., Nowak, V., Obländer, J., Pressler, J., Palme, I., Xanthopoulos, C., et al. (2016) · Blood · doi:10.1182/blood-2015-11-679167 · Cited by 127
The interplay of leukemia cells and the bone marrow microenvironment
Duarte, D., Hawkins, E. D., & Celso, C. L. (2018) · Blood · doi:10.1182/blood-2017-12-784132 · Cited by 147
Clonal evolution of acute myeloid leukemia from diagnosis to relapse
Vosberg, S., & Greif, P. A. (2019) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22806 · Cited by 151
De Novo Mutations Reflect Development and Aging of the Human Germline
Goldmann, J. M., Veltman, J. A., & Gilissen, C. (2019) · Trends in Genetics · doi:10.1016/j.tig.2019.08.005 · Cited by 144
Khakoo, S. S., Carter, P. D., Brown, G. M., Valeri, N., Picchia, S., Bali, M. A., Shaikh, R., Jones, T., Begum, R., Rana, I., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1996 · Cited by 142
“Poor responders (SD and PD) 8 (23) 2 (17) 3 (30) 7 (19) 2 (20) 8 (22) 0 5 (25)”
BackgroundInfluentialMRD in AML: The Role of New Techniques
Voso, M. T., Ottone, T., Lavorgna, S., Venditti, A., Maurillo, L., Lo‐Coco, F., & Buccisano, F. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00655 · Cited by 144
“However, some of the persisting mutations such as DNMT3A, ASXL1, and TET2 (49), collectively termed DTA, known to be frequent in clonal hematopoiesis (CHIP) (51, 52), did not have a prognostic role.”
BackgroundThe microenvironment in human myeloid malignancies: emerging concepts and therapeutic implications
Medyouf, H. (2017) · Blood · doi:10.1182/blood-2016-11-696070 · Cited by 129
Alborelli, I., Generali, D., Jermann, P. M., Cappelletti, M. R., Ferrero, G., Scaggiante, B., Bortul, M., Zanconati, F., Nicolet, S., Haegele, J., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1770-3 · Cited by 141
Ferrando, A. A., & López-Otín, C. (2017) · Nature Medicine · doi:10.1038/nm.4410 · Cited by 120
Somatic TP53 variants frequently confound germ-line testing results
Weitzel, J. N., Chao, E. C., Nehoray, B., Van Tongeren, L. R., LaDuca, H., Blazer, K. R., Slavin, T., Pesaran, T., Rybak, C., Solomon, I., et al. (2018) · Genetics in Medicine · doi:10.1038/gim.2017.196 · Cited by 127
Mutant ASXL1 cooperates with BAP1 to promote myeloid leukaemogenesis
Asada, S., Goyama, S., Inoue, D., Shikata, S., Takeda, R., Fukushima, T., Yonezawa, T., Fujino, T., Hayashi, Y., Kawabata, K. C., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05085-9 · Cited by 125
Longitudinal dynamics of clonal hematopoiesis identifies gene-specific fitness effects
Robertson, N. A., Latorre-Crespo, E., Terradas-Terradas, M., Lemos-Portela, J., Purcell, A. C., Livesey, B. J., Hillary, R. F., Murphy, L., Fawkes, A., MacGillivray, L., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01883-3 · Cited by 132
Multiparameter prediction of myeloid neoplasia risk
Gu, M., Kovilakam, S. C., Dunn, W. G., Marando, L., Barcena, C., Mohorianu, I., Smith, A., Kar, S. P., Fabre, M. A., Gerstung, M., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01472-1 · Cited by 132
“Recently, it became clear that in the majority of cases, myeloid neoplasms develop from clonal hematopoiesis (CH), their shared preclinical ancestor 3–6 .”
Clonal Hematopoiesis: Mechanisms Driving Dominance of Stem Cell Clones
Challen, G., & Goodell, M. A. (2020) · Blood · doi:10.1182/blood.2020006510 · Cited by 131
Jakobsen, N. A., Turkalj, S., Zeng, A. G. X., Stoilova, B., Metzner, M., Rahmig, S., Nagree, M. S., Shah, S., Moore, R., Usukhbayar, B., et al. (2024) · Cell Stem Cell · doi:10.1016/j.stem.2024.05.010 · Cited by 130
Hackl, H., Astanina, K., & Wieser, R. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0416-0 · Cited by 142
Losing Sense of Self and Surroundings: Hematopoietic Stem Cell Aging and Leukemic Transformation
Verovskaya, E. V., Dellorusso, P. V., & Passegué, E. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.04.006 · Cited by 127
Krebs, M. G., Malapelle, U., André, F., Paz-Ares, L., Schuler, M., Thomas, D. M., Vainer, G., Yoshino, T., & Rolfo, C. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.4457 · Cited by 126
Clonal hematopoiesis: Mutation-specific adaptation to environmental change
Florez, M. A., Tran, B. T., Wathan, T. K., DeGregori, J., Pietras, E. M., & King, K. Y. (2022) · Cell Stem Cell · doi:10.1016/j.stem.2022.05.006 · Cited by 129
Epigenetic Aging Signatures Are Coherently Modified in Cancer
Lin, Q., & Wagner, W. (2015) · PLOS Genetics · doi:10.1371/journal.pgen.1005334 · Cited by 128
“Somatic mutations are usually considered as tumor-initiating events [1].”
BackgroundExtracellular serine controls epidermal stem cell fate and tumour initiation
Baksh, S. C., Todorova, P. K., Gur-Cohen, S., Hurwitz, B., Ge, Y., Novak, J. S. S., Tierney, M. T., dela Cruz-Racelis, J., Fuchs, E., & Finley, L. W. S. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0525-9 · Cited by 128
Barbui, T., Thiele, J., Vannucchi, A. M., & Tefferi, A. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.64 · Cited by 140
Mupo, A., Seiler, M., Sathiaseelan, V, Pance, A., Yang, Y., Agrawal, A. A., Iorio, F., Bautista, R., Pacharne, S., Tzelepis, K., et al. (2017) · Leukemia · doi:10.1038/leu.2016.251 · Cited by 123
The Contribution of Mosaic Variants to Autism Spectrum Disorder
Freed, D., & Pevsner, J. (2016) · PLOS Genetics · doi:10.1371/journal.pgen.1006245 · Cited by 131
“In next-generation sequencing data, reads supporting the alternate allele at variant sites are known to be under-represented due to biases against non-reference alleles [25].”
BackgroundClonal evolution patterns in acute myeloid leukemia with NPM1 mutation
Cocciardi, S., Dolnik, A., Kapp‐Schwoerer, S., Rücker, F. G., Lux, S., Blätte, T. J., Skambraks, S., Krönke, J., Heidel, F. H., Schnoeder, T. M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09745-2 · Cited by 139
Hellmann, M. D., Nabet, B. Y., Rizvi, H., Chaudhuri, A. A., Wells, D. K., Dunphy, M. P. S., Chabon, J. J., Liu, C. L., Hui, A. B., Arbour, K. C., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3418 · Cited by 125
Somatic mutations and clonal hematopoiesis in congenital neutropenia
Xia, J., Miller, C. A., Baty, J., Ramesh, A., Jotte, M. R. M., Fulton, R. S., Vogel, T. P., Cooper, M. A., Walkovich, K. J., Makaryan, V., et al. (2018) · Blood · doi:10.1182/blood-2017-08-801985 · Cited by 126
“0 Median (range) 17 (4-34) 26 (3-47) 10 (0.”
Wang, S. A., Tam, W., Tsai, A. G., Arber, D. A., Hasserjian, R. P., Geyer, J. T., George, T. I., Czuchlewski, D. R., Foucar, K. K., Rogers, H. J., et al. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.75 · Cited by 129
Age-associated changes in human hematopoietic stem cells
Pang, W. W., Schrier, S. L., & Weissman, I. L. (2016) · Seminars in Hematology · doi:10.1053/j.seminhematol.2016.10.004 · Cited by 130
Liquid Biopsy in Clinical Management of Breast, Lung, and Colorectal Cancer
Hench, I. B., Hench, J., & Tolnay, M. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00009 · Cited by 128
“Somatic alterations accumulate in solid tissues and the hematopoietic system as a function of age (133).”
BackgroundClinical Implications of Clonal Hematopoiesis
Steensma, D. P. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.04.002 · Cited by 125
“Male sex and cigarette smoking are associated with a modestly increased risk of CHIP.1,22 A germline polymorphism in TERT, a gene encoding a component of the telomerase complex, is also associated with a higher likelihood of having CHIP, despite the absence of differences in telomere length between persons with wild-t…”
BackgroundInfluentialSanders, M. A., Chew, E., Flensburg, C., Zeilemaker, A., Miller, S. E., al Hinai, A. S., Bajel, A., Luiken, B., Rijken, M., Mclennan, T., et al. (2018) · Blood · doi:10.1182/blood-2018-05-852566 · Cited by 119
Sun, L., & Babushok, D. V. (2020) · Blood · doi:10.1182/blood.2019000940 · Cited by 136
Lemonnier, F., Cairns, R. A., Inoue, S., Li, W. Y., Dupuy, A., Broutin, S., Martin, N., Fataccioli, V., Pelletier, R., Wakeham, A., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1617929114 · Cited by 121
“This finding is consistent with the relatively high frequency of these mutations in clonal hematopoiesis of undetermined significance, especially among elderly patients (24, 25).”
ResultPrassek, V. V., Rothenberg‐Thurley, M., Sauerland, M. C., Herold, T., Janke, H., Ksienzyk, B., Konstandin, N. P., Görlich, D., Krug, U. O., Faldum, A., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.191536 · Cited by 131
“The high incidence of TET2, DNMT3A, SRSF2, ASXL1, TP53 and SF3B1 mutations in our patients is in agreement with reports showing that these genes are frequently mutated in age-associated clonal hematopoiesis.(26,32) Overall, 83% (126/151) of AML patients ≥75 years carried at least one mutation in one of these six genes.”
BackgroundResult
Metadata
- Authors
- Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., Purcell, S. M., Svantesson, O., Landén, M., Höglund, M., Lehmann, S., Gabriel, S. B., Moran, J. L., Lander, E. S., Sullivan, P. F., Sklar, P., Grönberg, H., Hultman, C. M., & McCarroll, S. A.
- Affiliations
- Harvard University (US)
- Karolinska Institutet (SE)
- Science for Life Laboratory (SE)
- Stanley Center for Psychiatric Research (US)
- Memorial Sloan Kettering Cancer Center (US)
- Massachusetts General Hospital (US)
- Icahn School of Medicine at Mount Sinai (US)
- University of Gothenburg (SE)
- Uppsala University Hospital (SE)
- Karolinska University Hospital (SE)
- Broad Institute (US)
- University of North Carolina at Chapel Hill (US)
- ORCID
- Genovese, Giulio
- Kähler, Anna K.
- Handsaker, Robert E.
- Lindberg, Johan
- Rose, Samuel A.
- Bakhoum, Samuel F.
- Mick, Eran
- Neale, Benjamin M.
- Fromer, Menachem
- Purcell, Shaun M.
- Landén, Mikael
- Höglund, Martin
- Lehmann, Sören
- Gabriel, Stacey B.
- Moran, Jennifer L.
- Lander, Eric S.
- Sullivan, Patrick F.
- Sklar, Pamela
- Grönberg, Henrik
- McCarroll, Steven A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-12-25
- Volume
- 371
- Issue
- 26
- Pages
- 2477-2487
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4290021
- OpenAlex
- W2126816979
- Cited by
- 3,531
- References
- 40
- Citations by year
- 2026: 240 · 2025: 293 · 2024: 315 · 2023: 363 · 2022: 386 · 2021: 360 · 2020: 356 · 2019: 310 · 2018: 294 · 2017: 254 · 2016: 215 · 2015: 134 · 2014: 6
- FWCI
- 143.98
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Mental Health (R01MH077139, RC2MH089905)
- National Human Genome Research Institute (R01HG006855, U54HG003067, R01HG005827)
- National Cancer Institute (P30CA014051)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Epidemiology › Multiple and Secondary Primary Cancers
- Keywords
- clonal hematopoiesis, somatic mutations, DNMT3A, ASXL1, TET2, acute myeloid leukemia, early cancer detection, bone marrow biopsy, cancer susceptibility
- MeSH terms
- Adult, Age Factors, Aged, Aged, 80 and over, Blood, Cell Transformation, Neoplastic, Clone Cells, DNA Mutational Analysis, Hematopoiesis, Hematopoietic Stem Cells, Humans, Middle Aged, Mutation, Risk Factors, Hematologic Neoplasms, Young Adult, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.